Step into the forefront of innovation at the 4th annual
Oligonucleotide Therapeutics and Delivery conference!
Deep dive into the latest breakthroughs in oligonucleotide development, regulatory compliance, and CMC considerations. Discover cutting-edge strategies to elevate oligonucleotide discovery and precision targeting. Explore optimized delivery methodologies for oligonucleotide-based therapies, propelling the frontier of oligonucleotide drug development forward.
Don't miss your chance to be part of this transformative event on 9 - 10 September.
Join us and shape the future of therapeutic advancement!
Why should you attend?
- Benchmark against leading big pharma case studies to advance your manufacturing and analytical strategies for advanced oligonucleotide synthesis
- Explore the potential of industry cross collaboration with insights from working groups, regulatory bodies and senior big pharma and biotech experts leading the way in driving advancements for genetic medicine
- Learn how AI is propelling drug discovery forward for sequence design and unlocking undruggable proteins and how this can translate to your pipelines
- Engage in the latest drug delivery technologies, optimising target specificity for RNA therapeutics and vaccines
Who should attend
Pharma and Biotech Directors, Managers and Heads of Departments of:
- RNA
- Genetic Medicine
- Oligonucleotide Discovery
- RNA Discovery
- New Modalities
- RNA Biology
- RNA Formulation and Delivery
- Targeted Delivery
- Clinical Development
- Pre-Clinical Development
- Oligonucleotide Chemistry
- Drug Discovery
- Target Discovery
- Medicinal Chemistry
- RNA Development
- RNA Vaccines
- RNA Biochemistry
Featured Speakers
- Alessandro Bonetti, Principal Scientist, R&D Biopharmaceuticals, AstraZeneca
- Daniel Elbaum, Chief Scientific Officer, QurAlis
- David Evans, CSO, Sirnaomics, Inc
- David Tew, Senior Scientific Director, Enzyme Engineering and Biocatalysts (E2B), GSK
- Heinrich Haas, Chief Technology Officer, NeoVac
- Joanna Hemming Taylor, Associate Principal Scientist, AstraZeneca
- Nagy Habib, Professor of Surgery, Imperial College London, Co-Founder, MiNA, Apterna and Dawn Therapeutics
- Peter Smith, Director, New Modalities Chemistry, AstraZeneca
- Priya Karmali, Chief Technology Officer, Capstan Therapeutics
- Rabia Khan, Founder & CEO, Serna.bio
- Samir Ounzain, Senior Chief Executive Officer and Scientific Co-Founder, HAYA Therapeutics
- Session Reserved for, BioPhorum
- Thierry Dorval, Head of Data Sciences & Data Management, Servier Pharmaceuticals
- Thomas Thum, Founder, Chief Scientific Officer and Chief Medical Officer, Cardior Pharmaceuticals GmbH
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Hilton London Kensington
179-199 Holland Park Ave, Kensington, W11 4UL
London, UK
